Skip to content
Cumberland Pharmaceuticals logo

Cumberland Pharmaceuticals

CPIX

Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops, and commercializes branded prescription products for hospital acute care, gastroenterology, and oncology markets.

Market cap
$105.33M+105%
Revenue$41.9M+2.1%
Net income-$7.4M-125%
Free cash flow$1.4M-23.9%
EPS (diluted)-$0.49-96.0%
Trailing twelve months · change vs. prior year

Earnings

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$8.5M
EPS estimate-$0.13

Financials

Q1 2026

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation & ratios

Valuation

See full
Market cap$105.33M+105%
Enterprise value$99.15M+141%
P/S2.5×+1.3×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Segments

By product

See full
Sancuso$2.9M+29.8%
Vibativ$2.1M-29.4%
Talicia$1.9M
Other revenue$168.9K-94.6%

Competitors

Profile

Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops, and commercializes branded prescription products for hospital acute care, gastroenterology, and oncology markets. The company leverages a targeted sales infrastructure and international partnerships to deliver unique medicines that address unmet medical needs in concentrated prescriber bases.

Competitive position

Cumberland maintains a niche position by focusing on concentrated medical specialties that can be served by small, targeted sales forces and by acquiring orphan or specialty drugs.

GeographiesUnited States, International
Customer segmentsAcute Care Providers, Specialist Physicians, Healthcare Systems
Business modelProduct-based, Licensing, Co-promotion
SuppliersContract Manufacturing Organizations, Academic Research Institutions, Raw Material Suppliers
CustomersWholesale Distributors, Hospitals, Retail Pharmacies, Group Purchasing Organizations
Listed2009
Employees91.0
CEOA. J. Kazimi
FilingsSEC EDGAR

Questions, answered.

What is Cumberland Pharmaceuticals's market cap?
Cumberland Pharmaceuticals (CPIX) has a market capitalization of $105.3M and trades on NASDAQ.
What is Cumberland Pharmaceuticals's revenue and profitability?
Cumberland Pharmaceuticals generated $41.9M in trailing twelve-month revenue with a net loss of $7.4M, representing a net margin of -17.6%. Gross margin stands at 82.9%, with free cash flow of $1.4M. These figures are based on the Q1 2026 filing.
Who are Cumberland Pharmaceuticals's competitors?
Cumberland Pharmaceuticals's key competitors include Baxter International, BridgeBio Pharma, Inc. Common Stock, Scienture Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Cumberland Pharmaceuticals partner with?
Cumberland Pharmaceuticals's notable partners include Perrigo Company, Poly Pharmaceuticals, Foxland Pharmaceuticals, Inc., and others.
What subsidiaries does Cumberland Pharmaceuticals have?
Cumberland Pharmaceuticals's subsidiaries include Cumberland Emerging Technologies, Talicia Holdings, Inc..
Where is Cumberland Pharmaceuticals headquartered?
Cumberland Pharmaceuticals is headquartered in United States of America and employs approximately 91 people. It has been publicly traded since 2009.